Gilead Sciences, Inc.
Stock Details
Is it expensive?
Trailing P/E Ratio
17.58
Forward P/E Ratio
13.48
PEG Ratio
0.33
11.72
Price-to-Sales (TTM)
5.39
6.82
18.93
Market Cap
160.39B
172.66B
Is it profitable?
Net Profit Margin (TTM)
30.99%
Gross Profit Margin
79.24%
Diluted EPS (TTM)
7.35
43.36%
29.74B
Is it growing?
4.40%
53.70%
Is it risky?
0.33
94.64
1.97
22.17B
Who owns it?
92.20%
0.12%
1.87%
1.24B
1.24B
Does it pay?
2.54%
43.40%
Sep 12, 2024
Sep 27, 2024
How much cash?
9.82B
10.81B
7.93B
7.91
- Price
- 129.16
- Percent Change
- -0.02 (0.02%)
- Previous Close
- 129.18
- Open
- 130.10
- Low
- 128.95
- High
- 131.66
52-Week Range Position (52WRP)
Fairly Priced
Fairly Priced
within its 1-year price range
$129.16
From 52W Low
+23.65%
From 52W High
-17.88%
Today
-0.02%
1Y Change
+16.93%
6M
$121.22
3M
$145.14
1M
$133.48
Today
$129.16
From 52W Low
+23.65%
From 52W High
-17.88%
Today
-0.02%
1Y Change
+16.93%
6M
$121.22
3M
$145.14
1M
$133.48
Today
$129.16
Fairly Priced
within its 1-year price range
$129.16
Multi-Timeframe Analysis (MTA)
Divergence
Timeframes disagree. Short and long-term momentum are pulling in different directions, which historically signals higher uncertainty and potential turning points. As reflected in the Multi-Timeframe Analysis (MTA) below.
1M
-3.2%
3M
-11.0%
6M
+6.6%
1Y
+16.9%
Rate of Change (ROC)
Accelerating
Price is falling 8.1x faster than usual. As reflected in the ROC Momentum below, which compares recent monthly gain vs its 12-month average pace.
Relative Volume (RVOL)
Low Volume
Very little activity today. Thin trading can exaggerate price moves in either direction. As reflected in the Relative Volume (RVOL) below.
- Name
- Gilead Sciences, Inc.
- Founded
- 1987
- CEO
- Daniel P. O'Day
- Employees
- 17,000
- Fiscal Year End
- Dec 31, 2024
- Address
333 Lakeside Drive
Foster City
California
94404
United States
- GICS Classification
- Health Care›Pharmaceuticals, Biotechnology & Life Sciences›Biotechnology
- Website
- www.gilead.com
Indicators
Operating Cash Flow
10.81B
Net Income
9.22B
Backed by Cash
1.17
Earnings closely match operating cash flow. This is the healthy baseline: profits are genuine and not artificially inflated.
Most investors only look at net income, which companies can manipulate through accounting rules. Cash flow is harder to fake. A ratio above 1.0 means every dollar of profit is backed by real cash.
Related Heatmaps
NASDAQ 100Index NASDAQ-100 - NDX |
S&P 500Index S&P 500 - SPX |
Indicators
Operating Cash Flow
10.81B
Net Income
9.22B
Backed by Cash
1.17
Earnings closely match operating cash flow. This is the healthy baseline: profits are genuine and not artificially inflated.
Most investors only look at net income, which companies can manipulate through accounting rules. Cash flow is harder to fake. A ratio above 1.0 means every dollar of profit is backed by real cash.
Stock Details
Is it expensive?
Trailing P/E Ratio
17.58
Forward P/E Ratio
13.48
PEG Ratio
0.33
11.72
Price-to-Sales (TTM)
5.39
6.82
18.93
Market Cap
160.39B
172.66B
Is it profitable?
Net Profit Margin (TTM)
30.99%
Gross Profit Margin
79.24%
Diluted EPS (TTM)
7.35
43.36%
29.74B
Is it growing?
4.40%
53.70%
Is it risky?
0.33
94.64
1.97
22.17B
Who owns it?
92.20%
0.12%
1.87%
1.24B
1.24B
Does it pay?
2.54%
43.40%
Sep 12, 2024
Sep 27, 2024
How much cash?
9.82B
10.81B
7.93B
7.91
- Price
- 129.16
- Percent Change
- -0.02 (0.02%)
- Previous Close
- 129.18
- Open
- 130.10
- Low
- 128.95
- High
- 131.66
52-Week Range Position (52WRP)
Fairly Priced
Fairly Priced
within its 1-year price range
$129.16
From 52W Low
+23.65%
From 52W High
-17.88%
Today
-0.02%
1Y Change
+16.93%
6M
$121.22
3M
$145.14
1M
$133.48
Today
$129.16
From 52W Low
+23.65%
From 52W High
-17.88%
Today
-0.02%
1Y Change
+16.93%
6M
$121.22
3M
$145.14
1M
$133.48
Today
$129.16
Fairly Priced
within its 1-year price range
$129.16
Multi-Timeframe Analysis (MTA)
Divergence
Timeframes disagree. Short and long-term momentum are pulling in different directions, which historically signals higher uncertainty and potential turning points. As reflected in the Multi-Timeframe Analysis (MTA) below.
1M
-3.2%
3M
-11.0%
6M
+6.6%
1Y
+16.9%
Rate of Change (ROC)
Accelerating
Price is falling 8.1x faster than usual. As reflected in the ROC Momentum below, which compares recent monthly gain vs its 12-month average pace.
Relative Volume (RVOL)
Low Volume
Very little activity today. Thin trading can exaggerate price moves in either direction. As reflected in the Relative Volume (RVOL) below.
- Name
- Gilead Sciences, Inc.
- Founded
- 1987
- CEO
- Daniel P. O'Day
- Employees
- 17,000
- Fiscal Year End
- Dec 31, 2024
- Address
333 Lakeside Drive
Foster City
California
94404
United States
- GICS Classification
- Health Care›Pharmaceuticals, Biotechnology & Life Sciences›Biotechnology
- Website
- www.gilead.com
Related Heatmaps
NASDAQ 100Index NASDAQ-100 - NDX |
S&P 500Index S&P 500 - SPX |